MINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383

eTOC

REVIEW  THE EVOLUTION OF IVF

Minerva Endocrinologica 2018 March;43(1):50-6

DOI: 10.23736/S0391-1977.17.02638-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Ovarian hyperstimulation syndrome management strategies: where are we going?

Ashley M. ESKEW, Kenan R. OMURTAG ✉

Department of Reproductive Endocrinology and Infertility, Washington University School of Medicine, St. Louis, MO, USA

PDF  

Ovarian hyperstimulation syndrome (OHSS) is one of the most frequent, serious and potentially lethal iatrogenic complications of controlled ovarian stimulation. Despite extensive research, the exact pathogenesis of this syndrome remains less clear, but there appears to be a relationship of increased vascular permeability mediated by HCG and other downstream mediators. Adequate experience with ovulation induction therapy and identifying patients with known risk factors are essential in preventing OHSS. As this is a completely iatrogenic disease numerous strategies have been investigated to help decrease the risk of OHSS and their effects on pregnancy and live birth rate. What follows is a review of the common strategies apply today to minimize risk of OHSS in patients undergoing assisted reproductive technologies.

KEY WORDS: Ovarian hyperstimulation syndrome - Gonadotropins - Leuprolide